Another stock that insiders are buying up is biopharmaceutical player Ziopharm Oncology (ZIOP), which is seeking to develop and commercialize a diverse portfolio of in-licensed cancer drugs that can address unmet medical needs. Insiders are buying into strength here since this stock is up over 16% in 2012.
Ziopharm Oncology has a market cap of $348 million and an enterprise value of $228 million. This stock trades at a rich valuation, with a price-to-sales of 744.27 and a price-to-book of 4.13. Its estimated growth rate for this year is -53.5%, and for next year it's pegged at -2.8%. This is a cash-rich company, since the total cash position on its balance sheet is $118.93 and its total debt is zero.A director and beneficial owner just bought 1,923,075 shares, or around $10 million worth of stock, at $5.20 per share. From a technical standpoint, ZIOP is currently trading above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently found big buying support at around $4.10 to $4.15 a share, and since then it has rallied back above its 50-day moving average toward its current price of $5.30 a share. This stock is now setting up to trigger a big breakout if it can manage to clear some near-term overhead resistance levels. If you're bullish on ZIOP, then one could be a buyer once it triggers a breakout trade above $5.32 to $5.34 (200-day) with strong volume. Look for volume that's near or above its three-month average action of 498,685 shares. At last check, volume today has already surpassed that level and the stock is trading at $5.25 a share. If that breakout triggers either today or in the near future, then traders should look for $5.90 or higher for ZIOP. ZIOP shows up on a list of 13 Stocks Bought and Sold by Hedge Funds for the most recently reported quarter.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV